SEC Company Response from Arcadia Biosciences, (RKDA) — Feb 5, 2026
Arcadia Biosciences, Inc.
Date: Feb. 5, 2026 · CIK: 0001469443 · Accession: 0001193125-26-039882
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292993
Letter
Arcadia Biosciences, Inc. 5956 Sherry Lane, Suite 2000 Dallas, TX 75225 February 5, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, N.E. Washington, D.C. 20549 Attn: Liz Packebusch, Esq. Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 (No. 333-292993) Filed on January 28, 2026 Acceleration Request Requested Date: February 10, 2026 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned registrant Arcadia Biosciences, Inc. (the "Company") hereby requests that the Securities and Exchange Commission take appropriate action to accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292993) (the “Registration Statement”) and declare such Registration Statement effective as of Tuesday, February 10, 2026, at 5:00 p.m., Eastern Time, or as soon thereafter as possible, or at such later time as the Company or its outside counsel, Weintraub Tobin, may orally request via telephone call to the Staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Securities Act of 1933, as amended. Please direct any questions or comments concerning this request to Kevin Kelso of Weintraub Tobin, at (916) 558-6110. Also, please orally notify Mr. Kelso when the Registration Statement has been declared effective. Very truly yours, Arcadia Biosciences, Inc. By: /s/ Thomas J. Schaefer Name: Thomas J. Schaefer Title: Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP Arcadia Biosciences, Inc. 5956 Sherry Lane, Suite 2000 Dallas, TX 75225 February 5, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, N.E. Washington, D.C. 20549 Attn: Liz Packebusch, Esq. Re: Arcadia Biosciences, Inc. Registration Statement on Form S-3 (No. 333-292993) Filed on January 28, 2026 Acceleration Request Requested Date: February 10, 2026 Requested Time: 5:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned registrant Arcadia Biosciences, Inc. (the "Company") hereby requests that the Securities and Exchange Commission take appropriate action to accelerate the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-292993) (the “Registration Statement”) and declare such Registration Statement effective as of Tuesday, February 10, 2026, at 5:00 p.m., Eastern Time, or as soon thereafter as possible, or at such later time as the Company or its outside counsel, Weintraub Tobin, may orally request via telephone call to the Staff. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Securities Act of 1933, as amended. Please direct any questions or comments concerning this request to Kevin Kelso of Weintraub Tobin, at (916) 558-6110. Also, please orally notify Mr. Kelso when the Registration Statement has been declared effective. Very truly yours, Arcadia Biosciences, Inc. By: /s/ Thomas J. Schaefer Name: Thomas J. Schaefer Title: Chief Executive Officer